{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:56:02Z","timestamp":1788270962301,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cpcardiol.2024.102464","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T06:18:16Z","timestamp":1708064296000},"page":"102464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-3831","authenticated-orcid":false,"given":"Sandeep","family":"Bhushan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102464_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1058998","article-title":"Assessing clinical and biomarker characteristics to optimize the benefits of Sacubitril\/Valsartan in heart failure","volume":"9","author":"Litwin","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"10106","key":"10.1016\/j.cpcardiol.2024.102464_bib0002","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102464_bib0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1139\/cjpp-2019-0531","article-title":"Butyrate improves cardiac function and sympathetic neural remodeling following myocardial infarction in rats","volume":"98","author":"Jiang","year":"2020","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112887","article-title":"Total flavonoids from Anchusa italica Retz. Improve cardiac function and attenuate cardiac remodeling post myocardial infarction in mice","volume":"257","author":"Wang","year":"2020","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/jcecho.jcecho_1_20","article-title":"The relationship between tumor necrosis factor alpha and left ventricular diastolic function","volume":"30","author":"El Missiri","year":"2020","journal-title":"J Cardiovasc Echogr"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/FJC.0000000000000456","article-title":"Proinflammatory cytokines mediate GPCR dysfunction","volume":"70","author":"Mohan","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acc.2019.07.002","article-title":"Cytokines in heart failure","volume":"93","author":"Stanciu","year":"2019","journal-title":"Adv Clin Chem"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102464_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-\u03b1 in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0009","article-title":"Cardiac fibroblasts and myocardial regeneration","volume":"9","author":"Chen","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling\u2014concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102464_bib0011","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCRESAHA.114.302819","article-title":"Dynamic changes in myocardial matrix and relevance to disease: translational perspectives","volume":"114","author":"Li","year":"2014","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102464_bib0012","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.cpcardiol.2024.102464_bib0013","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102464_bib0014","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0015","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2019.06.053","article-title":"Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102464_bib0016","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ejhf.2031","article-title":"Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article 'Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT'","volume":"23","author":"\u010culi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.105937","article-title":"Adherence-adjustment in placebo-controlled randomized trials: an application to the candesartan in heart failure randomized trial","volume":"90","author":"Murray","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"10.1016\/j.cpcardiol.2024.102464_bib0018","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102464_bib0019","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.cpcardiol.2024.102464_bib0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cpcardiol.2024.102464_bib0021","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102464_bib0022","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/08037051.2019.1625523","article-title":"The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist\/neprilysin inhibitor sacubitril\/valsartan in heart failure patients with hypertension and preserved ejection fraction","volume":"28","author":"Kjeldsen","year":"2019","journal-title":"Blood Press"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102464_bib0023","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102464_bib0024","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","article-title":"Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure","volume":"9","author":"Langenickel","year":"2012","journal-title":"Drug Discovery Today Therapeut Strat"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102464_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12958-020-0566-8","article-title":"Effects of cyclic adenosine monophosphate modulators on maturation and quality of vitrified-warmed germinal vesicle stage mouse oocytes","volume":"18","author":"Lee","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102464_bib0026","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/humrep\/dew020","article-title":"Extending prematuration with cAMP modulators enhances the cumulus contribution to oocyte antioxidant defence and oocyte quality via gap junctions","volume":"31","author":"Li","year":"2016","journal-title":"Hum Reprod"},{"issue":"22","key":"10.1016\/j.cpcardiol.2024.102464_bib0027","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2018345118","article-title":"The mRNA-destabilizing protein Tristetraprolin targets \"meiosis arrester\" Nppc mRNA in mammalian preovulatory follicles","volume":"118","author":"Xi","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"10.1016\/j.cpcardiol.2024.102464_bib0028","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: beyond natriuretic peptides","volume":"103","author":"Singh","year":"2017","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102464_bib0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102464_bib0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102464_bib0031","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"JJanuzzi","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102464_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005766","article-title":"N-terminal pro-B-type natriuretic peptide levels for risk prediction in patients with heart failure and preserved ejection fraction according to atrial fibrillation status","volume":"12","author":"Kristensen","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.cpcardiol.2024.102464_bib0033","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1358\/dof.2019.44.9.3071563","article-title":"European Society of Cardiology (ESC) congress 2019. Paris, France - August 31-September 4, 2019","volume":"44","author":"Dulsat","year":"2019","journal-title":"Drugs Future"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102464_bib0034","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cpcardiol.2024.102464_bib0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.cpcardiol.2024.102464_bib0036","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: from mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"issue":"40","key":"10.1016\/j.cpcardiol.2024.102464_bib0037","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"issue":"9851","key":"10.1016\/j.cpcardiol.2024.102464_bib0038","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.cpcardiol.2024.102464_bib0039","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102464_bib0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jchf.2019.07.005","article-title":"Circulating neprilysin in patients with heart failure and preserved ejection fraction","volume":"8","author":"Lyle","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"23","key":"10.1016\/j.cpcardiol.2024.102464_bib0041","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2024.102464_bib0042","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.639","article-title":"Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction","volume":"18","author":"Dini","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0043","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry","volume":"27","author":"Correale","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"13","key":"10.1016\/j.cpcardiol.2024.102464_bib0044","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015708","article-title":"Angiotensin receptor-neprilysin inhibition attenuates right ventricular remodeling in pulmonary hypertension","volume":"9","author":"Sharifi Kia","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.cpcardiol.2024.102464_bib0045","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.3390\/jcm9103159","article-title":"Effects of sacubitril\/valsartan on the right ventricular arterial coupling in patients with heart failure with reduced ejection fraction","volume":"9","author":"Masarone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2024.102464_bib0046","article-title":"Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation","volume":"25","author":"Bayard","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"25 Suppl","key":"10.1016\/j.cpcardiol.2024.102464_bib0047","doi-asserted-by":"crossref","first-page":"D22","DOI":"10.1016\/j.jacc.2013.10.027","article-title":"Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology","volume":"62","author":"Vonk-Noordegraaf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102464_bib0048","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1378\/chest.08-0492","article-title":"The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension","volume":"135","author":"Bogaard","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0049","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cardiores.2006.07.012","article-title":"cardiac fibroblasts, and the fibrotic response","volume":"74","author":"TGFbeta","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102464_bib0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D'Elia","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0051","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1152\/advan.00177.2016","article-title":"The renal and cardiovascular effects of natriuretic peptides","volume":"41","author":"Wong","year":"2017","journal-title":"Adv Physiol Educ"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102464_bib0052","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ehf2.12246","article-title":"Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril\/valsartan","volume":"5","author":"Pascual-Figal","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102464_bib0053","first-page":"747","article-title":"P773 Initiation of sacubitril\/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: an analysis of the TRANSITION study","volume":"40","author":"Wachter","year":"2019","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.cpcardiol.2024.102464_bib0054","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:50:15Z","timestamp":1758941415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0146280624001038"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102464","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of angiotensin receptor-neprilysin inhibition (ARNI) in improving ejection fraction and left and right ventricular remodeling in heart failure","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102464"}}